Selected metabolic aspects of elastin and collagen fiber proteolysis in diseases of the respiratory system – the significance of α1 antitrypsin deficiency

Agata Dżeliljii1, Wojciech Rokicki2, Krzysztof Karuś3

1National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
2Department of Thoracic Surgery, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland
3Center of Pulmonology and Thoracic Surgery, Bystra, Poland

Kardiochirurgia i Torakochirurgia Polska 2016; 13 (3): 242-247

Abstract
The process of elastin and collagen fiber destruction was presented based on the example of the changes taking place in the course of chronic obstructive pulmonary disease and primary spontaneous pneumothorax. In 1963, when analyzing patients with α1 antitrypsin deficiency, Dr Laurell and Dr Eriksson hypothesized that elastolysis plays a role in the pathogenesis of emphysema, which marked the beginning of studies aimed at analyzing this process. The present work concerns new scientific reports regarding the hypothesis. The most important risk factors include protease-antiprotease imbalance and α1 antitrypsin protein deficiency.

Key words: α1 antitrypsin, protease-antiprotease imbalance.

Introduction
Alpha-1 antitrypsin (AAT) is a potent antiprotease protecting lung tissue from the destructive influence of proteolytic enzymes. It is estimated that emphysema is caused by congenital AAT deficiency in 1–5% of cases [1], but no precise data are available. Full verification of an AAT deficiency diagnosis is only possible at the molecular level. The AAT protein is encoded by the SERPINA 1 gene, located on the long arm of chromosome 14 (14q32.1). Over 130 variants of AAT have been identified to date (Tab. I), the normal variant being PiMM. The main deficiency phenotypes causing severe AAT deficiency were labeled as PiMS, PiMZ, PiSZ, PiSS, and PiZZ. The occurrence of spontaneous pneumothorax is often the first symptom of AAT deficiency. The AAT deficiency is conducive to recurrent pneumothorax. Lin et al. presented a case of a 33-year-old pilot with pneumothorax as the first symptom of AAT protein deficiency. The AAT blood concentration was also significantly lowered, and further molecular diagnostics pointed to a mutation in the SERPINA 1 gene; the PiZZ genotype was established [2].

Sotcan et al. described a case of a 40-year-old woman, who was a tobacco smoker suffering from chronic obstructive pulmonary disease (COPD). Blood AAT was 72 mg/dl (laboratory norms: 200–300 mg/dl) [3]. Miravitlles et al. presented the results of enhanced diagnostics conducted in a 39-year-old woman, who was a former tobacco smoker (8 pack-years) with early-onset emphysema. A new variant of the AAT protein was found – YBARCELONA – PiYM. During a 6-year follow-up, no deterioration (clinical or radiological) occurred in the patient, who refrained from smoking tobacco in that period [4]. Early diagnosis of AAT deficiency can improve the patients’ quality of life and extend their survival.

Protease-antiprotease imbalance
Excessive proteolysis leads to the destruction of elastin and collagen fibers, which causes the restructuring of the respiratory tract. Higher activity of matrix metalloproteinases MMP-1, MMP-2, MMP-8, MMP-9, and MMP-12 originating from inflammatory cells, serine proteases (neutrophil elas-
| Variant | Prevalence | Variant name | Change in tertiary structure | Site of mutation (exon) | Change in amino acid sequence | Primary allele (exon) | Intracellular defect | Clinical manifestations |
|---------|------------|--------------|------------------------------|------------------------|------------------------------|-----------------------|---------------------|----------------------|
| Normal  | Common     | M1 (Ala213)  | –                            | III                    | –                            | –                     | –                   | –                    |
|         |            | M1 (Val213)  | –                            | –                      | Ala213Val (A213V)           | –                     | –                   | –                    |
| Common  | M2         | –            | –                            | II                     | Arg101His (R101H)           | M3                    | –                   | –                    |
|         | M2obernburg | –            | –                            | –                      | Gly148Trp (G148W)           | M1 (Ala213)           | –                   | –                    |
| Common  | M3         | –            | –                            | V                      | Glu376Asp (E376D)           | M1 (Val213)           | –                   | –                    |
|         | M4         | –            | –                            | II                     | Arg101His (R101H)           | M1 (Val213)           | –                   | –                    |
| Rare    | M5 berlin  | –            | –                            | II                     | Pro88Thr (P88T)             | M1 (Val213)           | –                   | –                    |
|         | MSalzburg   | –            | –                            | –                      | Ala34Thr (A34T)             | M1 (Val213)           | –                   | –                    |
| Rare    | M6 bonn    | –            | –                            | II                     | Ser45Phe (S45F)             | M1 (Ala213)           | –                   | –                    |
|         | M6 passau  | –            | –                            | –                      | Ala60Thr (A60T)             | M1 (Val213)           | –                   | –                    |
| Rare    | Munich     | –            | –                            | Outside critical area | Asp2Ala (D2A)               | M1 (Val213)           | –                   | –                    |
| Rare    | Xihrstchurc | –            | –                            | V                      | Glu363Lys (E363K)           | M1 (Val213)           | –                   | –                    |
| Rare    | Etokyo     | –            | –                            | V                      | Lys335Glu (K335E)           | M1 (Val213)           | –                   | –                    |
| Deficiency | Common   | Z            | s5A                          | V                      | Glu342Lys (E342K)           | M1 (Ala213)           | Aggregation         | Emphysema, liver diseases |
| Rare    | Zugsberg   | S3A          | V                            | Glu342Lys (E342K)       | M2                           | Aggregation           | Emphysema           |
| Rare    | Zbristol   | hC and hD    | II                           | Thr85Met (T85M)        | M1 (Val213)                  | Aggregation           | Emphysema, liver diseases |
| Common  | Siijama    | hB           | II                           | Ser53Phe (S53F)        | M1 (Val213)                  | Aggregation           | Emphysema, liver diseases |
| Rare    | I          | hA           | II                           | Arg39Cys (R39C)        | M1 (Val213)                  | Aggregation           | Emphysema, liver diseases |
| Rare    | Pduarte    | s3B and hC, hD | II, III                  | Asp256Val (D256V)     | M4                           | Degradation           | Emphysema, liver diseases |
| Rare    | Plowell    | s3B and hC, hD | III                        | Asp256Val (D256V)     | M1 (Val213)                  | Degradation           | Emphysema, liver diseases |
| Rare    | Mmalton    | s6B          | II                           | del Phe51/52           | M2                           | Aggregation           | Emphysema, liver diseases |
| Rare    | Mnichinan  | s6B          | II                           | del Phe51/52           | M1 (Val213)                  | Aggregation           | Emphysema            |
Table I. Cont.

| Variant | Prevalence | Variant name | Change in tertiary structure | Site of mutation (exon) | Change in amino acid sequence | Primary allele | Intracellular defect | Clinical manifestations |
|---------|------------|--------------|-----------------------------|------------------------|-----------------------------|----------------|----------------------|------------------------|
| Rare    | Mpalermo   | s6B          | II                          | del Phe 51/52          | M1 (Val213)                 | Aggregation    | Emphysema            |
| Rare    | Mineral springs | hB       | II                          | Gly67Glu (G67E)         | M1 (Ala213)                 | Degradation    | Emphysema            |
| Rare    | Mheerlen    | s4B          | V                           | Pro369Leu (P369L)       | M1 (Ala213)                 | Degradation    | Emphysema            |
| Rare    | Mwurzburg   | s4B          | V                           | Pro369Ser (P369S)       | M1 (Val213)                 | Degradation    | Emphysema            |
| Rare    | Wbethesda   | s5A          | V                           | Ala336Thr (A336T)       | M1 (Ala213)                 | Degradation    | Emphysema            |
| Rare    | Ybarcelona  | s3B and hG   | III, V                      | Asp256Val (D256V)       | M1 (Val213)                 | Aggregation/degradation | Emphysema         |
|         |             | (adjacent to s5A) |                | Pro391His (P391H)       |                             |                |                      |
| Dysfunctional | Common | Z            | V                           | Glu342Lys (E342K)       | M1 (Ala213)                 | Reduced NE inhibition | Emphysema, liver diseases |
| Rare    | Pittsburgh  | Active center | V                           | Met358Arg (M358A)       | M1 (Val213)                 | Thrombin inhibition, no NE inhibition | Bleeding diathesis |
| Rare    | F           | s3C          | III                         | Arg223Cys (R223C)       | M1 (Val213)                 | Reduced NE inhibition | Emphysema        |
| Rare    | Mineral springs | hB       | II                          | Gly67Glu (G67E)         | M1 (Ala213)                 | Reduced NE inhibition | Emphysema        |
| Null    | Rare        | QObolton     | s1C                         | Pro362 CCC-> del C-> change 5'->stop373 TAA | M1 (Val213) | Degradation | Emphysema          |
| Rare    | QObellingham | s3C         | III                         | Lys217stop              | M1 (Val213)                 | Degradation    | Emphysema            |
| Rare    | QOcardiff   | s3B and hG   | III                         | Asp256Val (D256V)       | M1 (Val213)                 | Degradation    | Respiratory infection |
| Rare    | QOgranite falls | hF       | II                          | Tyr160 stop             | M1 (Ala213)                 | No mRNA        | Emphysema            |
| Rare    | QOhong kong | s5A and s6A  | IV                          | Leu338 CTC->del TC-> change 5'->stop 334 TAA | M2 | Aggregation | Emphysema          |
| Rare    | QOisola di procida | –        | II–IV                       | Large deletion (10kb) in exons II-V | – | No mRNA | Emphysema          |
| Rare    | QOMattwa    | s4A          | V                           | 353insT-> change 3'-> stop376 | M1 (Val213) | Degradation | Emphysema          |
| Rare    | QOluwigshafen | hD         | II                          | Ile92Asn (I92N)         | M2 | Degradation | Emphysema          |
Methionine oxidation inactivates AAT, leading to its proteolytic degradation. The purpose of this mechanism may be to protect elastase when its high activity is required.

**Epidemiology**

Alpha-1 antitrypsin deficiency is a significant clinical problem. It is estimated that AATD, like cystic fibrosis and Down syndrome, is one of the most frequent genetic disorders found in the Caucasian race. The average age of patients diagnosed with AAT deficiency is 54.6 (SD = 13.2) years, but it is important to point out that in the group of patients with the PiZZ variant it is 49.4 (SD = 14.5) years [9–11]. The available data suggest that severe homozygous AAT deficiency (PiZZ) in Europe is more frequent in Scandinavian countries (allele frequency 2.3%) than in the south of the continent (allele frequency 1%), 1 in 4727 Caucasian neonates in Europe on average. Poland is one of the few European countries that does not have complete data on the prevalence of AATD [12, 13]. Research in this field started in Poland during the 1970s. Diagnostic procedures were conducted in a group of 3560 healthy individuals. A starch gel electrophoresis method was used for phenotype assessment; it is no longer used due to its low sensitivity. The following results were obtained: prevalence of PiZ – 1.4/1000 and PiS – 15.6/1000 [14]. The research was resumed in the 1990s, but it mainly focused on two regions of the country: Małopolska and Wielkopolska. The size of individual groups ranged between 423 and 859 subjects. The average estimated prevalence of PiZ and PiS was, respectively, 14.5/1000 and 10.9/1000 and of PiZZ – 1.91/1000 in different areas of the country: Małopolska and Wielkopolska. The size of individual groups ranged between 423 and 859 subjects. The average estimated prevalence of PiZ and PiS was, respectively, 14.5/1000 and 10.9/1000 and of PiZZ – 1.91/1000 in different areas of the country: Małopolska and Wielkopolska. The size of individual groups ranged between 423 and 859 subjects. The average estimated prevalence of PiZ and PiS was, respectively, 14.5/1000 and 10.9/1000 and of PiZZ – 1.91/1000 in different areas of the country: Małopolska and Wielkopolska. The size of individual groups ranged between 423 and 859 subjects.
Diagnostics

**Indications for diagnostics**

Epidemiological research confirms a relationship between AAT deficiency and the development of chronic lung diseases. An analysis conducted by the Canadian Thoracic Society (CTS) enabled the identification of the group of patients with high risk of AATD. According to the CTS, diagnostics should be conducted among patients with COPD diagnosed < 65 years of age and/or a smoking history of > 20 pack-years [20–27]. The common guidelines of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) recommend that AATD diagnostics should be conducted in patients with respiratory diseases in the case of: early-onset emphysema (< 45 years of age), emphysema not associated with smoking tobacco or environmental factors, and bronchiectasis of unclear etiology [28].

**Diagnostic methods**

Full verification of an AAT deficiency diagnosis and confirmation of the results of quantitative determination are only possible at the molecular level. In the case of AAT deficiency, such verification can only be provided by identifying the phenotype or genotype of the inhibitor. Isoelectric focusing is a widely used method for identifying AAT variants, facilitating the establishment of the type of the circulating AAT protein (phenotype). An alternative to this method is DNA analysis. The presence of a mutation in locus Pi responsible for the deficiency can be established directly with genetic tests [29, 30]. During the last two decades, the methods for identifying a genetic AAT deficit became simplified. Another unique achievement is the implementation of a test that enables the analysis of AAT concentration in several drops of blood collected on filter paper.

**When to collect the material**

Alpha-1 antitrypsin blood concentration is subject to fluctuations and may increase significantly during an inflammatory response (even 3- to 11-fold) and, to a lesser extent, during pregnancy and the use of oral hormonal contraception. In order to exclude an increase of acute-phase proteins resulting from tissue damage or an inflammatory response, it is necessary to additionally determine the concentration of C-reactive protein in the collected samples. The material should not be collected during treatment for pneumothorax, in the early postoperative period, or if features of infection are revealed.

**Alpha-1 antitrypsin deficiency**

Over 130 variants of AAT protein have been identified so far (Tab. I); they were divided into 4 classes, depending on the concentration and function of the protein in plasma. The first class includes M-allele proteins, constituting the most frequent variant in the Polish population (PiM1M1 homozygotes constitute 55% of all phenotypes, while PiM1M2 and PiM1M3 heterozygotes constitute from 5% to 10%). This variant ensures the proper functioning of AAT in plasma. The second class includes deficiency variants, which were defined as protein products accumulating inside cells or undergoing degradation in the liver. The most common deficiency alleles are Z and S.

The homozygous PiZZ variant is characterized by a protein concentration approximately 85% lower than that encountered in individuals with the normal PiMM genotype; it is associated with the most severe clinical manifestations of AAT deficiency. In turn, PiSS homozygotes exhibit approximately 40% lower AAT concentrations in comparison to healthy individuals. The PiSS variant as well as the heterozygous PiMS and PiMZ variants ensure normal inhibitor function in plasma. It is, however, important to note that smoking tobacco significantly influences the intensity of proteolysis. The combination of nicotinism and AAT concentrations below 40% of normal is associated with an increased risk of respiratory diseases. The third class is composed of null alleles (PiQO), resulting from the premature discontinuation of translation, partial deletion of a gene, or intracellular protein degradation. Consequently, they are not detectable in plasma. The rare QOgranite falls, QObellingham, and QOmattawa mutations may serve as examples. The last, fourth class is constituted by dysfunctional variants, which may not only be associated with the loss of physiological activity, but may also acquire new enzymatic properties through a specific mutation. The Pittsburgh protein is an example of a protein product that does not contain methionine in the active position for neutrophil elastase and loses the ability to block it. In plasma, however, it acts as a strong anticoagulant, leading to bleeding diathesis. Anomalies of the AAT protein underlie numerous pathologies of both local and systemic nature [31].

**Surgical treatment of patients with α1 antitrypsin deficiency**

According to a report published in 1995 by the International Society for Heart and Lung Transplantation, 12% of lung transplants were conducted due to advanced emphysema resulting from AAT deficiency [32]; 5-year survival was approximately 50% [33]. In later years (1995–2014), patients with AAT deficiency constituted 5.4% of lung transplant recipients (n = 2459), and the average survival was 6.5 years. Transplant failures may be influenced by the following factors: exacerbation of inflammatory response and release of acute-phase proteins as a result of injury associated with the invasive surgical procedure, lack of clear recommendations for the use of supplement therapy before and after the transplant, as well as the natural course of the disease. In a prospective study, Cassina et al. evaluated the results of surgical treatment after bilateral lung volume reduction surgery (LVRS) in patients with confirmed AAT deficiency (n = 12) and emphysema associated with long-term tobacco smoking (n = 18). The assessment of respiratory capacity was conducted in both groups, including the results of 6-minute walk tests, respiratory mechanics, and arterial blood gas. The parameters in both
groups were statistically insignificant with the exception of forced expiratory volume in 1st second (FEV$_1$), which was lower in the group of patients with AAT deficiency (24% vs. 31%, $p < 0.05$). After the procedures, both groups exhibited a significant improvement in respiratory capacity. However, in the group of AAT deficient patients, the measured improvement in respiratory capacity was 31%, lower in the group of patients with AAT deficiency (24% vs. 31%)

Conclusions

Smoking tobacco plays a significant role in the natural course of the disease.

In patients with AAT deficiency, this factor quickens the onset of the first clinical symptoms and is associated with the development of the severe form of the disease. Early emphysema requires enhanced diagnostics.

Alpha-1 antitrypsin deficiency is not a key issue in patients at risk of spontaneous pneumothorax, but it may constitute a significant burden leading to progressive degeneration of lung tissue [35–37]. The above data demonstrate the complexity of the discussed issue and point to the need for early diagnosis of AAT deficiency in risk groups, especially in patients qualified for surgical procedures.

Disclosure

Authors report no conflict of interest.

References

1. Abboud RT, Ford GT, Chapman KR, Standards Committee of Canadian Thoracic Society. Alpha-1 antitrypsin deficiency: a position statement of Canadian Thoracic Society. Can Resp J 2001; 8: 81-88.
2. Lin Y, Chiu WK, Chang H, Cheng YL, Chen JC. Spontaneous pneumothorax in flight as first manifestation of alpha-1 antitrypsin deficiency. Aviat Space Environ Med 2008; 79: 704-706.
3. Sotcan M, Copaci I, Enache M, Jurcuţ C, Duţescu V, Rusu C. A rare case of granulocyt obojętnych. Post Hig Med Dośw 2002; 56: 73-92.
4. Miravitlles M, Vila S, Jaroli R, de la Roza C, Rodriguez-Friaz F, Vidal R. Pulmonary emphysema due to alpha- antitrypsin deficiency: familial study of the YBARCE LONA variant. Chest 2003; 124: 404-406.
5. Barnes PJ. Mechanisms of COPD: Differences from asthma. Chest 2000; 177 (2 Suppl): 105S-147S.
6. Tomashefski Jr J, Cagle P, Farver C, Fraire A. Dall and Hammar’s Pulmonary Pathology. Vol. I, Nonneoplastic Lung Disease. Third edition, Springer, New York 2008.
7. Chorostowska-Wynimko J, Poptawksa B, Janclauskieni S. Alfa-1 antitypsyna: rola w fiziologii i patologii człowieka. Int Rev Allergol Clin Immunol Family Med 2012; 18: 22-28.
8. Roszkowcsa-Jakimiec W, Worawoma A, Gacko M, Maksimowicz T. Proteazy granzulocytów obojętnych. Post Hig Med Dosw 2002; 56: 73-92.
9. Blanco I, de Serres FJ, Fernandez-Bustillo E, Zhang Y, Sciurba FC, Duncan SR. Autoantibodies in patients with chronic obstructive pulmonary disease. J Heart Lung Transplant 1995; 14: 805-815.
10. Barnes PJ. Mechanisms of COPD: Differences from asthma. Chest 2000; 177 (2 Suppl): 105S-147S.